The inclusion of pregnant and breastfeeding women in the HIV clinical trial intervention for Pre-exposure Prophylaxis (PrEP) is important to curb the spread of the virus.
This was the consensus during a five-day virtual training organised by the New HIV Vaccine and Microbicide Advocacy Society (NHVMAS) to educate journalists on developments in the fight against HIV and how to address existing gaps.
Speaking during the training, the Executive Director of NHVMAS, Florita Durueke, said pregnant and breastfeeding women have a substantial risk of HIV infection, hence their involvement in trials is paramount.
